AB SA01

Drug Profile

AB SA01

Alternative Names: AB-SA01; AmpliPhage-002

Latest Information Update: 04 May 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Biocontrol
  • Developer AmpliPhi Biosciences Corporation; United States Army Medical Research and Materiel Command; University of Adelaide
  • Class Antibacterials; Bacteriophages
  • Mechanism of Action Bacterial DNA modulators; Bacterial RNA modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Staphylococcal infections

Most Recent Events

  • 19 Dec 2016 Final efficacy and adverse events data from a phase I trial in Staphylococcal infections (Treatment-resistant) released by AmpliPhi Biosciences
  • 05 Dec 2016 Adverse events data from a phase I trial in Staphylococcal infections (In volunteers) released by AmpliPhi
  • 05 Dec 2016 AmpliPhi plans a phase II trial for Staphylococcal infections in the US
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top